What Black Arrow Biotech Inc. does

Black Arrow Biotech OÜ is an Estonian-headquartered private company founded in 2024 that develops AI-driven tools and assets for peptide-based drug discovery. Its core product is JÜRI, a proprietary AI platform that performs generative peptide design, predictive screening of peptide sequences ranging from 5 to 50 amino acids, and toxicity classification including haemolytic properties. The company claims JÜRI operates more than 45 times faster than human expert teams and learns continuously from each engagement. Around JÜRI, Black Arrow offers three commercial surfaces: a fee-for-service Peptide Screening product with a 14-day typical turnaround; AI-derived Peptide Libraries sold with extensive customization (10 to 100,000 peptides, 5 to 40 amino acids, 1 to 100 mg, purity bands from >70% to >95%); and an internal drug pipeline anchored by BAC2539, an RNA therapeutic producing an anti-cancer peptide with a guidance and activation system. The company's primary customers are pharmaceutical and biotech researchers, supplemented by academic institutions, and it operates a sales-led, direct B2B motion with contact-based quoting. The only publicly disclosed customer outcome is a collaboration with the Department of Pharmacology at Democritus University of Thrace, where nine AI-derived anti-cancer peptides were tested against A549 lung cancer cells and two advanced to further testing. Black Arrow is founder-owned, has six named leaders across CEO, CTO, CBIO, CSO, COO, and SPM functions, and runs offices in Tallinn, Estonia and Caulfield, Australia.

Name

Black Arrow Biotech Inc.

Legal name

Black Arrow Biotech OÜ

Website

https://blackarrowbio.tech

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Black Arrow Biotech is an Estonian private company that builds the JÜRI AI platform for generative peptide design, screening, and library curation, selling fee-for-service tools and AI-derived peptide assets to pharmaceutical, biotech, and academic drug discovery researchers.

Ownership category

akta.pro rank

Product category

AI-Driven Peptide Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• AI peptide discovery
• Drug discovery platform
• Peptide screening services
• Machine learning therapeutics
• Bioinformatics drug development

Headquarters

HQ city

Tallinn

HQ country

Estonia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Peptide Screening Services: Fee-for-service solution where customers submit peptides (5-50 amino acids) for AI-driven screening with JÜRI. Customers receive detailed reports including peptide properties, statistical significance, accuracy and specificity metrics. Typical turnaround time is 14 days.
2. Peptide Library Sales: Sale of customized AI-derived peptide libraries with various options including peptide count (10 to 100,000), length (5-40 amino acids), quantity (1mg to 100mg), and purity levels (>70%, >80%, >90%, >95%). Libraries are available in multiple forms including powder, solution, coated plates, and with cleavable/non-cleavable options.
3. Drug Development Pipeline: Proprietary drug development using JÜRI for internal drug discovery, with the first drug candidate BAC2539 (an RNA drug producing anti-cancer peptide) in their pipeline for cancer treatment.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Black Arrow Biotech develops and operates JÜRI, an AI platform that screens and generates therapeutic peptides, and sells AI-driven peptide discovery services to pharmaceutical and biotech researchers. Commercial offerings include fee-for-service peptide screening (5–50 amino acids, ~14-day turnaround), customized AI-derived peptide libraries, and an internal drug development pipeline (lead candidate BAC2539, an RNA drug producing anti-cancer peptide). The company also licenses its underlying AI capability for downstream drug discovery applications.

Product overview

Black Arrow Biotech offers a unified platform of AI-powered peptide drug discovery services centered around their proprietary AI platform JÜRI. The portfolio includes: JÜRI (core AI engine for peptide generation and screening), Peptide Screening (fee-for-service analysis of 5-50 amino acid peptides), Peptide Libraries (AI-derived catalogues across cancer, anti-infective, neurological, metabolic and cosmetic categories), and BAC2539 (lead drug candidate in pipeline). These offerings work together as an integrated drug discovery ecosystem—from AI-driven peptide generation through screening, library selection, and therapeutic development.

Differentiator

Problem solved

Functional benefit

Brands

• JÜRI: AI-powered peptide screening and generation platform that accelerates drug discovery by identifying potential therapeutic candidates.

Products and services

• JÜRI AI Platform Leading-edge AI platform designed to revolutionize peptide screening and generation. JÜRI accelerates drug discovery by identifying potential therapeutic candidates more efficiently than traditional methods, capable of working more than 45x faster than human experts. It uses generative AI, machine learning, and computer-aided design to move from random peptide libraries to physical drug candidates with high likelihood of safety and effectiveness.
• Peptide Screening Service AI-driven fee-for-service platform that streamlines peptide screening, analyzing peptide sequences ranging from 5–50 amino acids with advanced algorithms to identify and optimize peptides for targeted therapeutic applications. Customers submit peptides and receive detailed reports with accuracy, specificity, and statistical significance metrics, validated against known positive and negative cases.
• Custom Peptide Libraries AI-derived peptide catalogues for high-throughput screening, meticulously curated using generative AI, machine learning, and computer-aided design. Includes diverse collections across Drug Delivery, Neurological, Anti-Infective, Metabolic Disease, Cancer, and Cosmetic categories, with configurable peptide count, length, quantity, and purity.
• BAC2539 (Drug Pipeline Candidate) First drug candidate in Black Arrow Biotech's development pipeline; an RNA drug that produces a potent anti-cancer peptide with a guidance and activation system intended for the treatment of various types of cancer.

Quantifiable outcome

• 45x faster peptide analysis compared to human expert teams
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Absci: US generative AI company designing de novo antibodies and other biologics with a wet-lab loop; overlaps with Black Arrow's generative AI biologics positioning but focuses on antibodies rather than therapeutic peptides.
• Iambic Therapeutics: US AI-driven drug discovery company combining a discovery platform with an internal clinical-stage pipeline; comparable in stage and approach but with broader modality scope than Black Arrow's peptide focus.
• LabGenius: UK AI-driven antibody engineering company that combines ML with automated experimentation; comparable in AI-for-biologics approach and B2B platform model but focused on antibody rather than peptide discovery.
• Etcembly: UK AI-immunology company designing TCR and antibody therapeutics using ML; comparable as an AI-engineered biologics platform serving pharma research, though narrower in target class than Black Arrow's peptide libraries.

Direct peers

• Peptilogics: US-based AI-driven peptide therapeutics company combining a platform with an internal clinical-stage pipeline; closely mirrors Black Arrow's services-plus-pipeline dual strategy in the peptide modality.
• Pepticom: Israel-based AI peptide drug design company that uses computational methods to discover peptide therapeutics; one of the closest direct comparables to Black Arrow's JÜRI platform approach in terms of target modality (peptides) and AI-led discovery model.
• Cradle: Dutch generative AI company engineering proteins and peptides with a B2B services and partnerships model; competes head-on with JÜRI in computational biologics design and serves a similar pharma/biotech research customer base.

Broad incumbents

• Isomorphic Labs: Alphabet-owned AI drug discovery company building a multi-modality discovery engine; well-capitalized incumbent whose expansion into biologics directly threatens smaller AI-discovery startups pitching into the same pharma accounts.
• Insilico Medicine: Global AI drug discovery company operating both an internal pipeline and a Pharma.AI partnership platform; broader target across small molecules and biologics but a key competitor for AI-driven discovery deals with enterprise pharma.
• Generate Biomedicines: Well-funded US generative biology company creating novel protein therapeutics using AI; broader scope across protein modalities but a direct competitor for AI-designed biologic discovery partnerships with large pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/black-arrow-biotech-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Black Arrow Biotech Inc.